gemcitabine
gemcitabine
Overview
Gemcitabine (brand name Gemzar) is a pyrimidine nucleoside analog antimetabolite widely used in the treatment of multiple solid tumors, including pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, biliary tract cancer, and bladder cancer. Its mechanism of action centers on intracellular phosphorylation to active diphosphate and triphosphate forms that interfere with DNA replication: the triphosphate form competes with deoxycytidine triphosphate for incorporation into elongating DNA strands, leading to chain termination and apoptosis, while the diphosphate form inhibits ribonucleotide reductase, depleting the nucleotide pool available for DNA synthesis. Because of this dual mechanism, gemcitabine exhibits broad cytotoxic activity and has become a cornerstone chemotherapeutic agent across oncology.
Despite its established clinical role, gemcitabine faces significant limitations including acquired drug resistance and off-target toxicities such as severe myelosuppression. These challenges have driven extensive contemporary research into combination strategies—pairing gemcitabine with immunotherapy agents, targeted inhibitors, and novel drug delivery platforms—as well as mechanistic investigations into the molecular pathways that govern chemoresistance. Gemcitabine's central position in first-line regimens for pancreatic cancer, biliary tract malignancies, and urothelial carcinoma ensures that it remains a reference comparator and backbone partner across a broad spectrum of experimental therapeutic contexts.
Recent Publications Focus
Below is a summary of the newest research publications targeting gemcitabine (sorted by publication date).
Recent clinical and preclinical investigations have explored gemcitabine-based combination regimens across multiple cancer types, with particular emphasis on immunotherapeutic integration and chemotherapy optimization. In muscle-invasive bladder cancer, durvalumab combined with gemcitabine and cisplatin followed by adjuvant durvalumab demonstrated statistically significant improvements in event-free survival and overall survival compared to chemotherapy alone [41678313]. Enfortumab vedotin plus pembrolizumab has emerged as the preferred first-line treatment for metastatic urothelial carcinoma, competing with gemcitabine plus cisplatin [42384383]. For intrahepatic cholangiocarcinoma, the GOLP regimen combining gemcitabine and oxaliplatin with lenvatinib and anti-PD-1 antibody has shown promising efficacy in advanced disease [41780001]. Tumor Treating Fields combined with gemcitabine and nab-paclitaxel induced immunogenic cell death, suppressed c-MYC expression, and enhanced systemic immune responses including dendritic cell activation and increased effector memory T cells in pancreatic cancer models [41760592]. A phase I/II study of gemcitabine with pembrolizumab in previously-treated advanced non-small cell lung cancer found that elevated frequencies of regulatory T cells near CD3 T cells at baseline correlated with improved treatment outcomes, suggesting tumor inflammation scoring may predict response [42126144].
Innovative nanomedicine platforms have been developed to overcome chemotherapy limitations, particularly in drug-resistant tumors. CD44-targeted cyclodextrin-hyaluronic acid nanoparticles co-loaded with gemcitabine and paclitaxel demonstrated enhanced cellular uptake, cytotoxicity, and apoptosis in both drug-sensitive and drug-resistant pancreatic cancer cells, with improved tumor growth inhibition and intratumoral accumulation in vivo [41966415]. Redox-responsive gemcitabine-quinine nanoassemblies designed to overcome multidrug resistance exhibited dual drug release in tumor-mimicking conditions, markedly suppressed P-glycoprotein expression, and promoted intracellular gemcitabine accumulation in glioblastoma models [42060886]. Biodegradable polymersomes encapsulating gemcitabine and copper peroxide nanoparticles, functionalized with hyaluronic acid to target CD44-overexpressing triple-negative breast cancer cells, generated robust reactive oxygen species production via Fenton-like reactions that simultaneously enhanced gemcitabine activation and promoted immunogenic cell death [41780685]. Losartan preconditioning transiently normalized the dense fibrotic tumor microenvironment of pancreatic ductal adenocarcinoma, enabling efficient delivery of an exosome-liposome hybrid nanoparticle co-encapsulating gemcitabine and IL-12 circular RNA, which suppressed tumor growth and prolonged survival while reducing systemic gemcitabine toxicity [41763269].
Biomarker-driven approaches and mechanistic studies have identified factors predicting gemcitabine efficacy and resistance across cancer types. Transcriptomic profiling identified higher DOT1L expression as a candidate biomarker for positive response to gemcitabine in cholangiocarcinoma, addressing the heterogeneous clinical response that characterizes this disease [42373229]. In breast cancer, the meiotic protein SYCP1, aberrantly reexpressed in tumors, promoted DNA damage repair and gemcitabine resistance through chromatin-bound regulation of genome maintenance genes; SYCP1 loss increased sensitivity to both cisplatin and gemcitabine [42418586]. Dose-dependent bidirectional effects were observed in a 4T1 breast cancer model, where low-dose gemcitabine unexpectedly promoted tumor progression through angiogenesis and myeloid-derived suppressor cell expansion, while higher doses suppressed tumor growth and reversed immunosuppressive myeloid skewing [41967213]. A deep learning model leveraging RNA sequencing data successfully predicted chemotherapy response to gemcitabine and cisplatin in urothelial carcinoma, potentially enabling treatment optimization and reduced unnecessary toxicity [42055629].
Synergistic drug combinations targeting specific cellular pathways have demonstrated enhanced antitumor efficacy. Andrographolide sensitized intrinsically gemcitabine-resistant intrahepatic cholangiocarcinoma cells to gemcitabine through inhibition of RRM2 and the JAK/STAT3 pathway [42113266]. Saikosaponin D enhanced the synergistic antitumor effect of gemcitabine in bladder cancer by targeting PI3K/AKT-mediated ferroptosis [41935433]. A spatiotemporally programmed nanovesicle delivering celecoxib and a gemcitabine prodrug resolved immunosuppressive signals in triple-negative breast cancer by sequentially suppressing prostaglandin E2-mediated immune suppression before triggering damage-associated molecular pattern-releasing cell death, converting gemcitabine from a weak to a potent immunogenic cell death inducer [42236688]. In pancreatic cancer, standard chemotherapy with gemcitabine and nab-paclitaxel combined with histone deacetylase inhibitors and simvastatin showed reproducible drug synergism across multiple European laboratories through harmonized protocols [42224741]. Mechanistic investigations in pancreatic ductal adenocarcinoma have highlighted the therapeutic potential of combining gemcitabine with novel compounds targeting aerobic glycolysis and drug resistance pathways, as well as combining low-dose gemcitabine with ATR kinase inhibitors in tumors harboring DNA damage repair gene alterations [42312894, 42055152, 41563386].